Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01653418 · OUTCOME

Number of Participants With Overall Survival (OS)

Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation · Source last updated 2014-10-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Median follow-up of 6 months (range: 6-12 months)

What was measured

OS is defined as the duration from the time of transplant to death or last follow-up.

Groups in this outcome

V-BEAM + Stem Cell Infusion

Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
V-BEAM + Stem Cell Infusion10

Reported measurements

Expired Day +3
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
V-BEAM + Stem Cell Infusion1Not reportedNot reportedNot reportedNot reported
Expired Day +18
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
V-BEAM + Stem Cell Infusion1Not reportedNot reportedNot reportedNot reported
Alive
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
V-BEAM + Stem Cell Infusion8Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Expired Day +3
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Expired Day +18
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        8
    title
    Alive
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
OS is defined as the duration from the time of transplant to death or last follow-up.
groups
  1. description
    Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0
    id
    OG000
    title
    V-BEAM + Stem Cell Infusion
param Type
NUMBER
reporting Status
POSTED
time Frame
Median follow-up of 6 months (range: 6-12 months)
title
Number of Participants With Overall Survival (OS)
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice